Purvalanol A, reported to cause an arrest of G1 and G2 phase in cancer cell cycle progression in vitro, is a known low nanomolar inhibitor of cyclin-dependent protein kinases (CDKs) that also shows submicromolar affinity (with an IC50 of 0.24 μM) for c-Src kinase [48]. Here, CSK is linked to cancer.